Linatab M 850

Indications

Linatab M is designed to be used alongside diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. It is suitable for patients when a combination of Linagliptin and Metformin Hydrochloride is clinically indicated.

Pharmacology

Linagliptin functions as a DPP-4 inhibitor, enhancing glycemic control in type 2 diabetes patients. By preventing the breakdown of incretin hormones (GLP-1 and GIP), it promotes insulin release from pancreatic beta cells in a glucose-dependent manner and reduces glucagon secretion.

Metformin Hydrochloride, an oral antihyperglycemic biguanide, effectively lowers both basal and postprandial plasma glucose levels. It operates by decreasing hepatic glucose production, reducing intestinal glucose absorption, and improving insulin sensitivity, thus preventing hypoglycemia.

Dosage & Administration

Immediate Release Tablets:

• Standard dosage is individualized, with a maximum of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Gradual dose escalation is recommended to minimize gastrointestinal side effects.

Extended Release Tablets:

• Administer 5 mg Linagliptin and 1000 mg Metformin Hydrochloride once daily with a meal.

Starting Dose:

• For new patients, initiate with 2.5 mg Linagliptin and 500 mg Metformin twice daily. Adjust as necessary for those already on Metformin or Linagliptin.

Interaction

Caution is advised when using cationic drugs or carbonic anhydrase inhibitors with Linatab M, as interactions may affect efficacy and increase the risk of metabolic acidosis.

Contraindications

Linatab M is contraindicated in individuals with known hypersensitivity to its components, renal impairment, or in acute metabolic acidosis conditions.

Side Effects

Common side effects include nasopharyngitis and diarrhea, with an increased risk of hypoglycemia when used with sulfonylureas.

Pregnancy & Lactation

Due to a lack of controlled studies, Linatab M should be used during pregnancy only when necessary, with caution advised for lactating mothers.

Precautions & Warnings

Monitor patients for lactic acidosis symptoms, especially those with compromised health. Discontinue immediately if pancreatitis is suspected.

Overdose Effects

In the case of overdose, supportive measures should be taken. Metformin is dialyzable, whereas Linagliptin is not significantly removed by dialysis.

Therapeutic Class

Combination oral hypoglycemic preparations.

Storage Conditions

Store Linatab M in a cool, dry place below 30°C, away from light and moisture, and out of reach of children.